Pulse oximetry is now the standard noninvasive method of measuring blood oxygenation in neonatal patients. Pulse oxygen saturation values (SpO 2 ) are measured on nearly every neonatal patient, and more and more frequently, are incorporated into modular "vital sign" monitors. In fact, SpO 2 is now generally accepted as the fifth vital sign. 1 It probably is considered more often and perhaps assigned an even greater clinical importance than heart rate, respiratory rate, blood pressure, or temperature. Although pulse oximetry has not completely replaced blood gas measurements, there are many neonatal patients who can be managed by pulse oximetry and less frequent measures of arterial or venous PCO 2 and pH.
Nearly universal acceptance of conventional pulse oximetry, however, is not without reservation. Although trials have shown that SpO 2 correlates very closely with blood oxygen saturation 2 and quite accurately predicts PaO 2 , 3 conventional pulse oximetry instrumentation to date has had difficulty in producing accurate and reliable SpO 2 values during subject motion 4 and low blood flow conditions. 5 This problem of motion artifact is inherent to conventional pulse oximeters, because motion adds another signal to the pulse waveform signal, thereby changing the apparent amounts of light transmitted to the photoreceptor at the two wavelengths, red (R) and infrared (IR), that are used to detect the relative proportions of oxyhemoglobin and deoxyhemoglobin (R/IR transmitted light ratio). 6 -8 Motion adds pulsatility to nonarterial blood components (e.g., venous blood), which are mistakenly included in the R/IR ratio generated by the pulsatile arterial blood. The magnitude of error in SpO 2 measurement will be influenced by the venous blood saturation, arterial signal amplitude, and magnitude of motion. 4, 8 The motion-added signal produces false SpO 2 values to the extent that the extra signal, which does not represent the arterial pulse oxyhemoglobin/deoxyhemoglobin signal, is large relative to the arterial pulse signal. When the motion is marked, absolutely or in relation to the arterial pulse signal during low peripheral blood flow conditions, the motion-added signal tends to predominate over the pulse signal, so that the R/IR ratio transmitted to the photoreceptor produces a false SpO 2 value. An additional and specific source of error in conventional pulse oximetry occurs when "noise" from a variety of signal inputs that are not part of the true arterial pulse signal is introduced equally into both the R and IR channels, driving the R/IR ratio toward unity (1.0). A R/IR ratio of 1.0, whether real or artifactual due to noise, predicts a saturation value of ϳ82% according to conventional pulse oximeter algorithms. 4, 8 Such motion and noise artifacts are disturbing. They also limit accurate assessment of oxygenation, particularly in the sickest of patients (those with low peripheral blood flow), who are most susceptible to erroneous saturation readings. Motion and noise artifacts also can lead to unintentional neglect of the patient's oxygenation, the pulse oximetry values, or both, 9, 10 and to inadvertent overtreatment of the falsely low SpO 2 values with excessive oxygen administration (Goldman JM, Petterson MT, Kopotic RJ, Barker SJ, submitted for publication). 11, 12 Recent conventional pulse oximetry methods to eliminate motion artifact include reporting only new, correct values, freezing and reporting of old values, or reporting zero. [13] [14] [15] These methods only cover up or ignore the true blood oxygenation and SpO 2 values, often for relatively long periods. Most medical personnel who do pay attention to the pulse oximeter carefully wait until the motion stops, the pulse waveform signal "looks good" (on those instruments that show it), and the pulse rate matches the heart rate. Such practices are costly in time, and they also emphasize that considerable periods of absent or inaccurate SpO 2 values are part of conventional pulse oximetry practice.
Periods of absent or inaccurate SpO 2 values due to motion artifact are not insignificant. Recent reports have documented as many as 6 changes in behavioral state per hour in preterm infants, with at least 10 changes that last Ն10 minutes per 4 hours. 16 Nursing interventions and noise independently result in significant changes in both the behavioral and physiological responses of infants studied. 17 Motion artifact during pulse oximetry recordings is dependent on behavioral state, and overall affects up to 50% of recorded traces. Such problems are worse during transport and more physically active periods such as resuscitations. 18, 19 These are situations in which accurate pulse oximetry values would improve understanding of the degree of abnormal oxygenation and the optimization of oxygen therapy and other necessary medical management.
Is there any new approach to significantly decrease or eliminate motion artifact? Several preliminary reports now have documented that a new electronic signal processing technique and sensor design, called "signal extraction technology" (SET) by Masimo Corporation (Irvine, CA), markedly decreases false SpO 2 values during patient motion 12,20 -22 and improves the accuracy of SpO 2 values during conditions of low peripheral blood flow when even minimal motion can
overwhelm the pulse signal. 5, 18 The Food and Drug Administration has approved the accuracy of SET during motion and low perfusion conditions in all patients, including neonates (reference document available on the Food and Drug Administration web site: http://www .fda.gov/cdrh/pdf/k990966.pdf). SET also more accurately and reliably detects true and false bradycardic events; these improvements are accomplished without reducing the instrument's ability to capture true alarm conditions. 20 It is impressive to watch a Masimo oximeter provide SpO 2 values from a moving extremity that match those provided by a reference conventional oximeter from a nonmoving extremity, while SpO 2 values from conventional oximeters on the same moving extremity vary widely. Its only limitation, according to personal observations, is that that some clinicians have had difficulty understanding the explanations of the physics and electronics that form the basis of SET.
But is SET more valuable than conventional pulse oximetry? At present there is limited published literature (see Refs. 4 and 22), but several manuscripts are under review (Goldman JM, Petterson MT, Kopotic RJ, Barker SJ, submitted for publication; Ref. 25) , and numerous abstracts are available (see particularly Refs. 12, 18, and 20 -28). All come to the same conclusion: the new Masimo SET technology markedly reduces motion artifact while preserving accuracy, even under low flow and low blood oxygenation conditions. Publication of these reports should establish the accuracy and reliability of this new technology. Broadly based clinical experience may preclude the need for further extensive clinical trials. Future clinical trials will be helpful and perhaps necessary, however, to address how well the use of this new technology improves clinical care and outcomes. Such applications trials should include evaluations of nursing time and effort, medical judgements about routine oxygen deficits and oxygen therapy, and assessments of usefulness in high-motion situations such as high-activity behavioral states, transport, low peripheral blood flow conditions, and resuscitations. As new information becomes available from current research trials regarding novel aspects of oxygen therapy, this new instrumentation should also be tested for its ability to help the clinician more accurately and reliably produce and control selected blood oxygen values. These values might be used to help treat certain conditions, such as the vasoproliferative phase of prethreshold retinopathy of prematurity (the National Institutes of Health supplemental therapeutic oxygen for prethreshold retinopathy of prematurity trial addressing this possibility has just been completed) 29 or prevent others, such as pulmonary hypertension or the vasoconstrictive phase of retinopathy of prematurity. Clinical trials also might address home use for the detection of apnea and bradycardia and the prevention of related life-threatening events. Instrumentation that is markedly more accurate and reliable, with much greater sensitivity and specificity, might offer a definite advantage over current homemonitoring systems, which have notoriously high rates of false alarms. In all of these studies, attention to improved safe use of oxygen is paramount. A more accurate and reliable pulse oximeter should have the capacity to produce safer oxygen administration. Applications studies should provide reliable data to support this point.
Clearly, the fifth vital sign, SpO 2 , is here, and here to stay. It is a highly valuable measure of blood oxygenation and the overall health of the patient. But conventional pulse oximetry has needed technical improvement to eliminate motion artifact and improve accuracy and reliability during low flow and oxygenation conditions. SET provides this needed improvement. Clinical applications trials can now focus on demonstrating that the improved accuracy and reliability of this new technology are clinically important, and perhaps necessary, for improved nursing and medical management, patient care, and patient outcomes. Such studies will provide valuable data to guide the safe and effective use of oxygen therapy. Already it appears reasonable to conclude that more accurately and reliably monitored and maintained oxygenation will benefit patient management and patient outcomes. SET pulse oximeters do not cost more than conventional pulse oximeters, and because of their much improved accuracy and reliability, they have the potential, in contrast to other noninvasive methods of measuring blood oxygenation, to reduce costly blood gas analyses. Thus, we have every reason to use SET now, even while we await the results of more rigorous applications trials to determine the long-term benefit of this new, more accurate approach to pulse oximetry.
